ZLAB - Zai Lab - Stock Price & Dividends

Zai Lab Limited is a biopharmaceutical company that focuses on developing and commercializing innovative therapies to address unmet medical needs in various disease areas, including oncology, autoimmune disorders, infectious diseases, and neuroscience.

The company has a diverse portfolio of commercial products, including Zejula, a poly polymerase 1/2 inhibitor for treating cancer; Optune, a cancer therapy that uses electric fields to kill tumor cells; NUZYRA, an antibiotic for acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; Qinlock, a treatment for gastrointestinal stromal tumors; and VYVGART, a human IgG1 antibody fragment for myasthenia gravis.

Zai Lab is also developing a range of promising pipeline products, including Tumor Treating Fields, a portable device that delivers electric fields to treat cancer; Repotrectinib, a tyrosine kinase inhibitor for treating cancer patients with ROS1 and TRK A/B/C mutations; Tisotumab vedotin, an antibody drug conjugate for cancer treatment; Adagrasib, a targeted therapy for treating KRAS-G12C-mutated non-small cell lung cancer, colorectal cancer, and pancreatic cancer; and Bemarituzumab, a treatment for gastric and gastroesophageal junction cancer patients.

In addition, the company is developing Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for treating serious infections caused by Acinetobacter; and KarXT, a treatment for psychiatric and neurological conditions. Zai Lab has established partnerships with several leading pharmaceutical companies, including Tesaro, NovoCure, Deciphera, Paratek Bermuda, argenx, BMS, Mirati, Amgen, and Innoviva, to develop and commercialize its pipeline products.

Headquartered in Shanghai, China, Zai Lab was founded in 2013 and has built a strong reputation for its innovative approach to drug development and commercialization. The company's website can be accessed at https://www.zailaboratory.com.